4i22: Difference between revisions

Revision as of 14:07, 28 November 2012 view source OCA (talk \| contribs) Bots, Bureaucrats, journal, Administrators 3,330,058 edits m Protected "4i22" [edit=sysop:move=sysop] ← Older edit		Revision as of 20:46, 12 December 2012 view source OCA (talk \| contribs) Bots, Bureaucrats, journal, Administrators 3,330,058 edits No edit summary Newer edit →
Line 5:		Line 5:
	Authors: Gajiwala, K.S., Feng, J., Ferre, R., Ryan, K., Brodsky, O., Stewart, A.		Authors: Gajiwala, K.S., Feng, J., Ferre, R., Ryan, K., Brodsky, O., Stewart, A.

	Description: Structure of the monomeric (V948R)gefitinib/erlotinib resistant double mutant (L858R+T790M)EGFR kinase domain co-crystallized with gefitinib		Description: Structure of the monomeric (V948R)gefitinib/erlotinib resistant double mutant (L858R+T790M) EGFR kinase domain co-crystallized with gefitinib

Navigation menu